Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Drug manufacturer Novo Nordisk announced a new experimental weight-loss pill to treat obesity in development called amycretin ...

The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

The drug, called amycretin, helped volunteer patients lose a whopping 13 percent of their body weight over just 12 weeks. That means the new pill may be even more effective than the company's ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Why? Results from a Phase I trial of a new amycretin pill indicate that a highly effective and less intrusive weight loss drug is on the way, providing an alternative to the injection-based Ozempic.

Novo Nordisk’s (NVO) oral amycretin, which targets both GLP-1 and hunger-affecting pancreatic hormone amylin, produced an eye-popping 13.1% placebo-adjusted weight loss in its highest dose ...

But fear not, Novo Nordisk is now developing a possibly cheaper weight loss medication, a pill called amycretin, which has indications that it could be even more effective in helping people lose ...

It also has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly has orforglipron, an oral GLP-1 in phase 3. At the Seeking ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...